Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Novick

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Plos One|September 12, 2024
Hit screening with multivariate robust outlier detectionHui Sun Leong, Tianhui Zhang, Adam Corrigan, et al.
AAPS Pharmscitech|June 25, 2009
A two one-sided parametric tolerance interval test for control of delivered dose uniformity--part 3--investigation of robustness to deviations from normalitySteven Novick, David Christopher, Monisha Dey, et al.
AAPS Pharmscitech|June 25, 2009
A two one-sided parametric tolerance interval test for control of delivered dose uniformity. Part 1--characterization of FDA proposed testSteven Novick, David Christopher, Monisha Dey, et al.
Journal of Biomolecular Screening|June 21, 2013
The effect of initial purity on the stability of solutions in storageIoana Popa-Burke, Steven Novick, Charles A Lane, et al.
Pharmaceutical Statistics|May 30, 2019
Detecting bliss synergy in in vivo combination studies with a tumor kinetic modelWei Zhao, Paolo Vicini, Steven Novick, et al.
Journal of Cancer Research and Clinical Oncology|September 24, 2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 studyAndreas Hochhaus, Philipp D le Coutre, Hagop M Kantarjian, et al.
ACS Chemical Biology|March 21, 2024
Integrated Proteomics Characterization of NLRP3 Inflammasome Inhibitor MCC950 in Monocytic Cell Line Confirms Direct MCC950 Engagement with Endogenous NLRP3Heng Zhao, Praveen Kumar, Tiago Jose Paschoal Sobreira, et al.
Journal of Cancer Research and Clinical Oncology|May 24, 2015
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyAndreas Hochhaus, Michele Baccarani, Francis J Giles, et al.
Microorganisms|July 2, 2021
Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic RegimenVancheswaran Gopalakrishnan, Elizabeth Ashley Dozier, Matthew S Glover, et al.
Clinical Pharmacokinetics|July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic MalignanciesKen Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Plos One|September 12, 2024
Hit screening with multivariate robust outlier detectionHui Sun Leong, Tianhui Zhang, Adam Corrigan, et al.
AAPS Pharmscitech|June 25, 2009
A two one-sided parametric tolerance interval test for control of delivered dose uniformity--part 3--investigation of robustness to deviations from normalitySteven Novick, David Christopher, Monisha Dey, et al.
AAPS Pharmscitech|June 25, 2009
A two one-sided parametric tolerance interval test for control of delivered dose uniformity. Part 1--characterization of FDA proposed testSteven Novick, David Christopher, Monisha Dey, et al.
Journal of Biomolecular Screening|June 21, 2013
The effect of initial purity on the stability of solutions in storageIoana Popa-Burke, Steven Novick, Charles A Lane, et al.
Pharmaceutical Statistics|May 30, 2019
Detecting bliss synergy in in vivo combination studies with a tumor kinetic modelWei Zhao, Paolo Vicini, Steven Novick, et al.
Journal of Cancer Research and Clinical Oncology|September 24, 2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 studyAndreas Hochhaus, Philipp D le Coutre, Hagop M Kantarjian, et al.
ACS Chemical Biology|March 21, 2024
Integrated Proteomics Characterization of NLRP3 Inflammasome Inhibitor MCC950 in Monocytic Cell Line Confirms Direct MCC950 Engagement with Endogenous NLRP3Heng Zhao, Praveen Kumar, Tiago Jose Paschoal Sobreira, et al.
Journal of Cancer Research and Clinical Oncology|May 24, 2015
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyAndreas Hochhaus, Michele Baccarani, Francis J Giles, et al.
Microorganisms|July 2, 2021
Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic RegimenVancheswaran Gopalakrishnan, Elizabeth Ashley Dozier, Matthew S Glover, et al.
Clinical Pharmacokinetics|July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic MalignanciesKen Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Pageof 4